Cargando…

ACE Inhibitor/Angiotensin Receptor Blocker Use Patterns in Advanced CKD and Risk of Kidney Failure and Death

RATIONALE & OBJECTIVE: The use of renin-angiotensin system (RAS) inhibitors is standard of care in people with early to moderate chronic kidney disease (CKD). Less is known regarding the efficacy of RAS inhibitors in very advanced CKD. In this study, we describe patterns of use of RAS inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arora, Nayan, Katz, Ronit, Bansal, Nisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380396/ https://www.ncbi.nlm.nih.gov/pubmed/32734244 http://dx.doi.org/10.1016/j.xkme.2019.12.007

Ejemplares similares

Renin-Angiotensin System Inhibitors in Advanced CKD: a #NephJC Editorial on STOP-ACEi
por: Thanabalasingam, Susan, et al.
Publicado: (2023)

Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study
por: Chiu, Michael H., et al.
Publicado: (2018)

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
por: Chae, Young Kwang, et al.
Publicado: (2013)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

Mortality Burden and Life-Years Lost Across the Age Spectrum for Adults Living with CKD
por: Kula, Alexander J., et al.
Publicado: (2023)

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?
por: Manga, Pravin
Publicado: (2020)

Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease
por: Shen, Jian, et al.
Publicado: (2016)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis
por: Turgeon, Ricky D., et al.
Publicado: (2019)

Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients
por: Naimark, David Malcolm Joseph
Publicado: (2022)

Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients
por: Ramspek, Chava L., et al.
Publicado: (2022)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Mechanisms by which angiotensin-receptor blockers increase ACE2 levels
por: Ferrario, Carlos M., et al.
Publicado: (2020)

Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease – Demystifying controversies
por: Muneer, Kader, et al.
Publicado: (2017)

ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Wang, Yueying, et al.
Publicado: (2020)

Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers
por: Lee, Ivan T., et al.
Publicado: (2020)

Vitamin D Metabolic Ratio and Risks of Death and CKD Progression
por: Bansal, Nisha, et al.
Publicado: (2019)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis
por: Ye, Huizhen, et al.
Publicado: (2020)

Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study
por: Parit, Rahul, et al.
Publicado: (2021)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes
por: Benter, Ibrahim F., et al.
Publicado: (2013)

Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women
por: Bea, Jennifer W., et al.
Publicado: (2018)

Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Amat-Santos, Ignacio J., et al.
Publicado: (2020)

Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients
por: LaClair, Heather J., et al.
Publicado: (2021)

Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers
por: Chao, Chia-Ter
Publicado: (2011)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease
por: Vasavada, Nina, et al.
Publicado: (2009)

Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade
por: Lin, Chih-Ching, et al.
Publicado: (2017)

APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
por: Young, Bessie A., et al.
Publicado: (2021)

AT(1) receptor blocker, but not an ACE inhibitor, prevents kidneys from hypoperfusion during congestive heart failure in normotensive and hypertensive rats
por: Kratky, Vojtech, et al.
Publicado: (2021)

Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy
por: Malfertheiner, Peter, et al.
Publicado: (2018)

COVID-19 and ACE -inhibitors and angiotensin receptor blockers-: The need to differentiate between early infection and acute lung injury
por: GonzÃ¡lez-Rayas, JosÃ© Manuel, et al.
Publicado: (2020)

Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2021)

Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD
por: Wouda, Rosa D, et al.
Publicado: (2021)

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
por: Feidakis, Athanasios, et al.
Publicado: (2021)

Treatment of heart failure with ACE inhibitors and beta-blockers: What is next? Aldosterone receptor antagonists?
por: van der Horst, Iwan C. C., et al.
Publicado: (2007)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_v47o7fkdipd0ul9iol5ggiq45p